Author(s):
Sejal Tukaram Patel, Sunil P. Pawar, Amitkumar R. Dhankani, Mansi A. Dhnkani
Email(s):
sejalpatel1322001@gmail.com
DOI:
10.52711/2231-5675.2025.00039 
Address:
Sejal Tukaram Patel*, Sunil P. Pawar, Amitkumar R. Dhankani, Mansi A. Dhnkani
P.S.G.V.P Mandal’s College of Pharmacy Shahada, Nandurbar -425409, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 4,
Year - 2025
ABSTRACT:
A research presents the development and validation of a reliable and robust reverse-phase high-performance liquid chromatography (RP-HPLC) method for the quantitative estimation of Fimasartan in pharmaceutical tablet formulations. Fimasartan, a selective non-peptide angiotensin II type 1 (AT1) receptor blocker, is widely prescribed for managing essential hypertension. Regulatory standards. The method employed a Phenomenex C18 column under isocratic conditions, using a mobile phase consisting of acetonitrile and 0.05% orthophosphoric acid in water in a 75:25 (v/v) ratio. Chromatographic separation was achieved at a flow rate of 1.0 mL/min, with UV detection at 262 nm. The method exhibited excellent linearity within the concentration range of 10.0–30.0 µg/mL, with a correlation coefficient (R²) of 0.99998. The limits of detection (LOD) and quantification (LOQ) were found to be 0.156 µg/mL and 0.472 µg/mL, respectively. Validation, carried out according to ICH Q2(R1) guidelines, confirmed the method’s accuracy, with recovery results ranging from 98.90% to 100.89%. The method also demonstrated high precision (%RSD < 1.5), specificity, and robustness when subjected to deliberate variations in chromatographic parameters. Stability studies confirmed that sample solutions remained stable for at least 24 hours, while filtration tests indicated no significant analyte loss when using PVDF or nylon syringe filters. The validated method was successfully applied for the assay of commercially marketed Fimasartan tablets (Fimagen 60 mg), delivering consistent and reproducible outcomes. Overall, the proposed RP-HPLC method is simple, rapid, and highly suitable for routine quality control and analysis of Fimasartan in both bulk and finished dosage forms.
Cite this article:
Sejal Tukaram Patel, Sunil P. Pawar, Amitkumar R. Dhankani, Mansi A. Dhnkani. Analytical Method Development and Validation for Estimation of Fimasartan in Bulk Drug and Pharmaceutical Dosage Form. Asian Journal of Pharmaceutical Analysis. 2025; 15(4):249-5. doi: 10.52711/2231-5675.2025.00039
Cite(Electronic):
Sejal Tukaram Patel, Sunil P. Pawar, Amitkumar R. Dhankani, Mansi A. Dhnkani. Analytical Method Development and Validation for Estimation of Fimasartan in Bulk Drug and Pharmaceutical Dosage Form. Asian Journal of Pharmaceutical Analysis. 2025; 15(4):249-5. doi: 10.52711/2231-5675.2025.00039 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-4-1
REFERENCES:
1. Lee, S.Y., Lee, H.Y., and Kim, M.G. Pharmacokinetics and tolerability of Fimasartan, a novel angiotensin II receptor antagonist, in healthy subjects. Clinical Therapeutics. 2011; 33(5): 670–682.
2. Park, J. Y., Shin, K. H., and Rhee, Y. Pharmacodynamic and pharmacokinetic evaluation of Fimasartan. Drug Design, Development and Therapy. 2013; 7: 935–945.
3. PubChem, “Fimasartan.” Accessed: Jun. 15, 2025. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/9870652
4. Kim, S.H., et al. Discovery and preclinical evaluation of Fimasartan, a novel angiotensin receptor blocker. Bioorganic and Medicinal Chemistry Letters. 2010; 20(6): 2190–2193.
5. International Conference on Harmonisation (ICH). (2005). Validation of Analytical Procedures: Text and Methodology Q2 (R1).
6. Blessy, M., Patel, R. D., Prajapati, P. N., and Agrawal, Y. K. Development of forced degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical Analysis. 2014; 4(3): 159–165.
7. Shaikh, K. A., Patil, S. D., and Devkhile, A. B. Development and validation of UV spectrophotometric method for estimation of Fimasartan in tablet dosage form. International Journal of Pharmaceutical Sciences and Research. 2013; 4(5): 1767–1771
8. Sharma, P., et al. Development and validation of stability-indicating RP-HPLC method for the estimation of Fimasartan in tablet dosage form. Journal of Chromatographic Science. 2017; 55(9): 899–904.
9. Sarangi, R., et al. Development and validation of a rapid UPLC method for determination of Fimasartan in bulk and pharmaceutical dosage form. Indian Journal of Pharmaceutical Sciences. 2019; 81(2): 381–386.
10. Das, S., et al. Development and validation of a sensitive LC–MS/MS method for the determination of Fimasartan in human plasma: Application to a pharmacokinetic study. Biomedical Chromatography. 2018; 32(2): e4044.
11. Y. Choi, S. Lee, I. J. Jang, and K. S. Yu. Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers. Drug Des. Devel. Ther. 2018; 12: 2301–2309 doi: 10.2147/DDDT.S165171.
12. H. W. Moon, A. M. Yousaf, K. H. Cho, C. S. Yong, J. O. Kim, and H.-G. Choi. Evaluation of stability and simultaneous determination of fimasartan and amlodipine by a HPLC method in combination tablets. Asian J. Pharm. Sci. 2014; 9(3): 123–128.